GlassScriptPhysician profile
Adam Maclauchlan
NPI 1457702896
$5,091.67
in general payments reported to CMS, 2019-2025
44 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $583 · 2023: $1,775 · 2024: $1,258 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.66 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $711.01 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $559.12 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $508.45 | 2022-2025 | |
| Novo Nordisk INC | $493.16 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $369.48 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $240.50 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.51 | 2023-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $189.31 | 2023-2025 | Gemtesa |
| Amgen INC. | $185.51 | 2022-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $155.92 | 2022-2025 | |
| Pfizer INC. | $139.43 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.21 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.97 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $98.79 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $91.13 | 2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.49 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Exact Sciences Corporation | $78.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $77.75 | 2024-2025 | Auvelity |
| Corium, LLC | $55.75 | 2023 | Adlarity |
| Amneal Pharmaceuticals LLC | $53.59 | 2023-2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $47.87 | 2023 | |
| Phathom Pharmaceuticals, INC. | $46.65 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $41.88 | 2024-2025 | Ajovy |
| Halozyme INC | $38.72 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $37.47 | 2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $34.64 | 2024-2025 | Rexulti |
| Antares Pharma, INC. | $30.22 | 2024 | Xyosted |
| Merck Sharp & Dohme LLC | $29.54 | 2022-2024 | Verquvo |
| Tolmar, INC. | $28.51 | 2023-2025 | Jatenzo |
| Esperion Therapeutics, INC. | $28.50 | 2024-2025 | Nexletol |
| Horizon Therapeutics Plc | $20.74 | 2023 | Krystexxa |
| Vanda Pharmaceuticals INC. | $19.66 | 2024 | Fanapt |
| Ultragenyx Pharmaceutical INC. | $19.52 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.07 | 2022 | |
| Dexcom, INC. | $15.99 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $15.90 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Viatris Specialty LLC | $15.77 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $14.69 | 2025 | Zoryve |
| Lundbeck LLC | $14.30 | 2025 | Rexulti |
| Mylan Specialty L.P. | $14.29 | 2023 | Yupelri |
| Tris Pharma INC | $13.92 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $13.13 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $12.10 | 2022 | |
| Currax Pharmaceuticals LLC | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Maclauchlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.